Structure Therapeutics Inc. (NASDAQ:GPCR) Stake Lifted by XTX Topco Ltd

XTX Topco Ltd increased its position in shares of Structure Therapeutics Inc. (NASDAQ:GPCR) by 100.9% during the 3rd quarter, Holdings Channel.com reports. The firm owned 11,938 shares of the company’s stock after buying an additional 5,997 shares during the quarter. XTX Topco Ltd’s holdings in Structure Therapeutics were worth $524,000 at the end of the most recent reporting period.

Other institutional investors have also recently added to or reduced their stakes in the company. Zimmer Partners LP increased its position in shares of Structure Therapeutics by 19.2% during the 3rd quarter. Zimmer Partners LP now owns 211,100 shares of the company’s stock valued at $9,265,000 after purchasing an additional 34,000 shares during the period. Wellington Management Group LLP boosted its stake in Structure Therapeutics by 2.9% during the third quarter. Wellington Management Group LLP now owns 7,769,771 shares of the company’s stock valued at $341,015,000 after buying an additional 221,851 shares in the last quarter. Wexford Capital LP grew its holdings in Structure Therapeutics by 5.4% during the third quarter. Wexford Capital LP now owns 98,223 shares of the company’s stock worth $4,311,000 after acquiring an additional 5,000 shares during the period. State Street Corp raised its position in Structure Therapeutics by 27.0% in the third quarter. State Street Corp now owns 12,295 shares of the company’s stock worth $540,000 after acquiring an additional 2,611 shares in the last quarter. Finally, Readystate Asset Management LP acquired a new stake in Structure Therapeutics in the 3rd quarter valued at about $3,687,000. 91.78% of the stock is currently owned by institutional investors and hedge funds.

Analyst Ratings Changes

GPCR has been the topic of several recent research reports. Morgan Stanley assumed coverage on shares of Structure Therapeutics in a research note on Monday, September 23rd. They issued an “overweight” rating and a $118.00 price objective on the stock. Cantor Fitzgerald reaffirmed an “overweight” rating and issued a $65.00 price target on shares of Structure Therapeutics in a report on Monday, September 23rd. Finally, HC Wainwright initiated coverage on Structure Therapeutics in a research note on Wednesday, December 4th. They set a “buy” rating and a $80.00 price objective for the company. Seven equities research analysts have rated the stock with a buy rating, Based on data from MarketBeat.com, Structure Therapeutics presently has an average rating of “Buy” and an average price target of $85.67.

Structure Therapeutics Stock Performance

Shares of NASDAQ:GPCR opened at $31.25 on Friday. The firm has a 50 day simple moving average of $36.56 and a 200 day simple moving average of $39.22. Structure Therapeutics Inc. has a 52 week low of $26.61 and a 52 week high of $62.74. The company has a market cap of $1.79 billion, a PE ratio of -42.81 and a beta of -3.41.

About Structure Therapeutics

Structure Therapeutics Inc, a clinical stage global biopharmaceutical company, develops and delivers novel oral therapeutics to treat a range of chronic diseases with unmet medical needs. The company’s lead product candidate is GSBR-1290, an oral and biased small molecule agonist of glucagon-like-peptide-1 receptor, a validated G-protein-coupled receptors (GPCRs) drug target for type-2 diabetes mellitus and obesity.